With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

CVS Health CEO Karen Lynch has stepped down with company shares down 19% this year and the national drugstore chain struggling. Lynch will be replaced by David Joyner, who will attempt to steer ...

Per- and polyfluoroalkyl substances (PFAS) have finally been proposed for a complete and permanent ban. These groups of over ...

The new offer is for a 31% general wage increase over five years instead of the previous offer’s 26% increase over four years ...

In this article, we will look at the 7 Best Small-Cap Value Stocks to Buy According to Hedge Funds. Let’s look at where ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business ...

Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock has ...

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

The global biosimilar and biologics market is anticipated to witness significant expansion, with market size expected to grow ...